NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Single-Dose Ciprofloxacin is as Effective as 12-Dose Erythromycin in Childhood Cholera: Results of a Randomized Controlled Trial.

KHAN WA, RAHMAN MM, SAHA D, CHOWDHURY HR, SALAM MA, BENNISH ML; Interscience Conference on Antimicrobial Agents and Chemotherapy (43rd: 2003: Chicago, Ill.).

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2003 Sep 14-17; 43: abstract no. G-1551.

ICDDR,B, Dhaka, Bangladesh.

BACKGROUND: In endemic areas cholera is primarily an infection of children. We have previously shown that single-dose ciprofloxacin is effective in the treatment of cholera in adults; in this study we examined its efficacy in childhood cholera. METHODS: Children 2-15 y with diarrhea /= 20 ml/kg body weight during a 4 h observation period, and who had evidence of V. cholerae infection on dark-field microscopy were randomly assigned to receive either a single 20 mg/kg dose of ciprofloxacin or 12.5 mg/kg of erythromycin every 6 h for 3 d. Treatment was not blinded. Children remained in hospital for 5 d, stool volume was measured every 6 h, and a stool culture obtained daily. Therapy clinically failed if patients had watery stools after study day 2, and bacteriologically failed if V. cholerae O1 or O139 was isolated after study day 2. Children were followed for 6 w after discharge for development or arthropathy. RESULTS: 180 children were enrolled in the study; 13 were excluded from analysis because of vomiting within 30 m of receiving study drug, 4 because they left before completion of the study, and 1 because V. cholerae was not isolated. Therapy was clinically successful in 47 (60%) of 78 ciprofloxacin and 46 (55%) of 84 erythromycin-treated patients (P = NS). Children receiving ciprofloxacin were less likely to vomit (58% vs. 74%; P = 0.046); had fewer stools (median 15 vs. 21; P = 0.050) and a lesser volume of stool (median 152 vs. 196ml/kg; P = 0.048) than children receiving erythromycin. Bacteriologic failure occurred more often in ciprofloxacin-treated patients (58% vs. 30%; P < 0.001). Arthropathy was not observed in any patient. CONCLUSIONS: Single-dose ciprofloxacin is a safe and effective alternative to 12-dose erythromycin therapy for the treatment of childhood cholera.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Adult
  • Child
  • Cholera
  • Cholera Vaccines
  • Ciprofloxacin
  • Clinical Trials as Topic
  • Diarrhea
  • Double-Blind Method
  • Erythromycin
  • Feces
  • Humans
  • Single Person
  • Vibrio cholerae
Other ID:
  • GWAIDS0026339
UI: 102265963

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov